Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2018-08-23 Investor Presentation
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
2018 Full Year Results Investor Presentation 30 pages 1.4MB
Investor Presentation Classification · 95% confidence The document is titled 'Mayne Pharma Group Limited FY18 Results Presentation 24 August 2018' and contains detailed financial results for the fiscal year 2018, including EBITDA, net income, segment performance, and operational highlights. It includes forward-looking statements, non-IFRS financial information, and detailed segment analysis. The document is a presentation format, typically used to communicate financial results and business strategy to investors and analysts. It is not a full annual report (10-K), nor is it a brief earnings release (ER) since it contains extensive financial data and analysis. It is not a transcript of a call, nor an audit report or regulatory filing. The presence of detailed financial results, operational highlights, and forward-looking statements in a presentation format aligns with the definition of an Investor Presentation (IP). The document length (15,000 characters) and content support this classification with high confidence.
2018-08-23 English
Appendix 3B 9 pages 690.6KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is an announcement related to the issuance of new securities, specifically ordinary shares issued as part of consideration for an acquisition. It includes detailed information about the class, number, issue price, purpose of the securities, and compliance with ASX rules. The document also contains a quotation agreement for the securities to be listed on the ASX and details about employee options issued under an employee share option plan. This type of document is a formal announcement of a new share issue and application for quotation of additional securities, which aligns with the definition of a Share Issue/Capital Change filing. It is not a full financial report, earnings release, or regulatory filing, but a specific announcement about capital changes.
2018-07-26 English
Mayne Pharma acquires generic Efudex in the US 2 pages 270.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 23 July 2018 about Mayne Pharma's acquisition of generic Efudex from Spear Pharmaceuticals. It details the acquisition terms, strategic rationale, and financial implications such as EPS accretion and EBITDA multiples. The content focuses on a corporate transaction involving acquisition and financing details, not on financial results, regulatory filings, or management changes. There is no indication of it being a full annual or interim report, audit report, or earnings release. The document is a corporate announcement about a financing and acquisition event, fitting the Capital/Financing Update category.
2018-07-22 English
Lapse of employee options and option exercise 1 pag
Transaction in Own Shares Classification · 95% confidence The document is a short announcement from Mayne Pharma Group Limited regarding employee share options that have lapsed and been exercised. It details the number of options, expiry dates, and exercise prices, and explains the use of forfeited shares to satisfy option exercises. There is no financial statement, comprehensive financial data, or detailed report content. The document is an update on share options, which fits best under the category of Transaction in Own Shares (POS), as it relates to the company's handling of its own shares through employee option exercises and forfeitures. The document length is short and it is not a report or regulatory filing but a specific transaction announcement.
2018-07-15 English
Mayne Pharma further strengthens Board with new Director 2 pages 252.9KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 28 June 2018 about the appointment of a new director, Mr. Patrick Blake, to the Board of Mayne Pharma Group Limited. It details his background and the company's statement welcoming him. There is no financial data, no report attached or referenced as being published, and no mention of voting results or other report types. The content clearly fits the category of announcing changes in the company's board of directors. The document length is 3646 characters, which is relatively short and consistent with a management or board announcement rather than a full report or presentation.
2018-06-27 English
Initial Director's Interest Notice 2 pages 514.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, with no securities held. This matches the description of a Director's Dealing report, which involves reporting personal share transactions or interests by company directors. The document length is short and focused solely on director interests, not financial results or other report types.
2018-06-27 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.